Search by job, company or skills
Hospitals/Healthcare/Diagnostics
Department- DD&IT Product Supply
Do you want to play a key role in the Warehouse 4.0 journey in Novo Nordisk by implementing the SAP Extended Warehouse Management (EWM) on the latest S/4 HANA technology as warehouse management and control system Are you seeking an opportunity to drive IT solution implementation and engage with stakeholders across IT, the Manufacturing Sites and the Supply Chain Organisation If so, the position as SAP EWM Advanced Business Analyst can be the right fit for putting your expertise to work while at the same time making a difference for patients living with diabetes. Apply now!
The position
As an SAP EWM Senior Business Analyst, you will:
Qualifications
We are looking for candidates who have:
About the department
DD&IT Product Supply, within the Global IT Organisation, is a unit responsible for more than 40 global IT systems at Novo Nordisk including the operation, maintenance, support, and development of these systems. The systems are used on a global scale by all areas of the business from R&D to Sales and are critical to the execution of key business processes such as development, manufacturing, sales, finance, etc. The strategic objective of the unit is to be the IT partner for the business ensuring that we provide the IT solutions and support which is needed to support the Novo Nordisk production solution as well as supply chain needs worldwide. The team you will be working with comprises highly skilled and passionate project members based primarily in Denmark and India.
Working at Novo Nordisk
Novo Nordisk is a leading global healthcare company with a 100-year legacy of driving change to defeat serious chronic diseases. Building on our strong legacy within diabetes, we are growing massively and expanding our commitment, reaching millions around the world and impacting more than 40 million patient lives daily. All of this has made us one of the 20 most valuable companies in the world by market cap. Our success relies on the joint potential and collaboration of our more than 63,000 employees around the world. We recognise the importance of the unique skills and perspectives our people bring to the table, and we work continuously to bring out the best in them. Working at Novo Nordisk, we're working toward something bigger than ourselves, and it's a collective effort. Join us! Together, we go further. Together, we're life changing.
Contact
To submit your application, please upload your CV online (click on Apply and follow the instructions).
Deadline
26th November 2024
Disclaimer
It has been brought to our attention that there have recently been instances of fraudulent job offers, purporting to be from Novo Nordisk and/or its affiliate companies. The individuals or organizations sending these false employment offers may pose as a Novo Nordisk recruiter or representative and request personal information, purchasing of equipment or funds to further the recruitment process or offer paid trainings. Be advised that Novo Nordisk does not extend unsolicited employment offers. Furthermore, Novo Nordisk does not charge prospective employees with fees or make requests for funding as a part of the recruitment process.
We commit to an inclusive recruitment process and equality of opportunity for all our job applicants.
At Novo Nordisk we recognize that it is no longer good enough to aspire to be the best company in the world. We need to aspire to be the best company for the world and we know that this is only possible with talented employees with diverse perspectives, backgrounds and cultures. We are therefore committed to creating an inclusive culture that celebrates the diversity of our employees, the patients we serve and communities we operate in. Together, we're life changing.
Date Posted: 07/11/2024
Job ID: 99510753
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in eight countries, and affiliates or offices in 5 countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 25% of its shares and a supermajority (45%) of its voting shares.